Cygnus Technologies, LLC

Cygnus Technologies, part of Maravai LifeSciences, provides best-in-class analytical tools and solutions to help companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. As the biopharmaceutical industry’s partner in analytics for host cell proteins (HCP), other process-related impurities, and viral clearance, Cygnus’ off-the-shelf products and custom services ultimately improve bioprocess development for faster regulatory approval and better clinical outcomes. Founded by Ken Hoffman in 1997, Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies; as of April 1, 2026, Cygnus’ off-the shelf and custom assays have been used for lot release testing of multiple licensed novel biologics, biosimilars, vaccines and 28 FDA- and EMA-approved cell and gene therapies. Cygnus continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus offers an innovative approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technologies, available through its products and custom assays/services, set the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Located in Leland, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.